Greek
Global Sustain
Sign up to the newsletter


Novartis Hellas SACI

Member: Gold
Since: 01.03.2016

12th km National Road Athens-Lamia, Metamorfosi, 144 51 Athens, Greece
RSS

Social

For Novartis, Corporate Responsibility (CR) is inextricably linked to our business strategy. For us, it is our belief that sustainability and responsibility are essential to our long-term business success. On this journey we have the support of our people, our driving force, at the same time with the commitment and involvement of senior executives. Our patient-centric approach is a reference point in the formulation of CR priorities, which is based on two strategic pillars that are consistent with the relevant UN sustainable development goals: a) access to healthcare and b) responsible business.

Novartis Hellas contributed a total of $271 million to the Greek GDP in 2018 and generated almost 2,000 jobs directly, indirectly and induced according to the findings of the Impact Valuation study, which was conducted by the mother company for its local markets. The outcome confirms the company’s commitment towards sustainable development, as well as its focus on patients and the Greek society in general. Aligned with the company’s global vision to help people live better and longer lives, Novartis Hellas invested in 2018 $4,3 mil. in Research and Development. The company conducted 79 clinical trials, which benefited more than 2,000 Greek patients and offered 43 therapies (established and innovative) that reached 1,4 million patients generated 24,5 thousand QALYS (Quality Adjusted Life Years). The social impact of the Novartis these therapies to the country’s GDP contribution through healthier people reached $469 million.